To casual observers, Genentech Inc.'s Jan. 5 tweet might have seemed oddly mysterious. "FDA grants Genentech medicine supplemental approval in rheumatoid arthritis," read the tweet. But which medicine was it? And what exactly did the FDA say? Read More
